Floatz logo

CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE

Osteolymphoma

Trans Tasman Radiation Oncology GroupSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Osteolymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Trans Tasman Radiation Oncology Group
N/AD
Cyclophosphamide
Trans Tasman Radiation Oncology Group
N/AD
Inno-206
Trans Tasman Radiation Oncology Group
N/AD

Same molecule, other indications

CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE is also rated in:

infantile spasmsDormant
BBB
Indicative ·
79 / 100
View asset →
non-Hodgkin lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
castration-resistant prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →